Abstract: An aminoalcohol derivative which is a ceramide analogue, and a medicament, especially an agent for treating neuronal diseases and an agent for protecting brain, comprising the same.
Abstract: This invention provides conjugates useful for xenotransplantation which comprise a galactose &agr;1,3 galactosyl (&agr;Gal) epitope conjugated to a valency platform molecule, preferably a chemically defined valency platform molecule which allows precise valency. The invention also provides compositions comprising these conjugates, and methods (such as methods for inducing tolerance) using these conjugates and compositions.
Type:
Grant
Filed:
December 8, 1999
Date of Patent:
June 4, 2002
Assignee:
La Jolla Pharmaceutical Company
Inventors:
Richard M. Jack, David S. Jones, Lin Yu
Abstract: The use of carbohydrate derivatives in or for making a topical composition for promoting skin exfoliation is disclosed. The use of said composition of controlling intrinsic and extrinsic skin ageing, as well as a non-therapeutic skin treatment method for skin exfoliation, are also disclosed.
Type:
Grant
Filed:
June 16, 1998
Date of Patent:
May 21, 2002
Assignee:
L'Oreal
Inventors:
Michel Philippe, Catherine Ebenhan-Nappe
Abstract: The present invention provides convergent processes for preparing epothilones, desoxyepothilones, and analogues thereof. The present invention further provides novel compositions and methods for the treatment of cancer and additionally provides methods for the treatment of cancer which has developed a multi-drug phenotype.
Type:
Application
Filed:
March 1, 2001
Publication date:
May 16, 2002
Inventors:
Samuel J. Danishefsky, Shawn J. Stachel, Chul Bom Lee, Mark D. Chappell, Ting-Chao Chou, Zhicai Wu
Abstract: Novel nocathiacin derivatives have been prepared by both biotransformation and chemical methods. A novel nocathiacin derivative, nocathiacin IV, was prepared by either incubation of protease from Streptomyces griseus (Sigma, Cat# P5147) with nocathiacin I in DMF or by chemical methods. Fermentation of Actinoplanes sp. ATCC 53771 in the presence of nocathiacin IV produces a new compound nocathiacin IV 6-deoxyglucoside. Both nocathiacin IV and nocathiacin IV 6-deoxyglucoside have broad spectrum antibiotic activity against Gram-positive bacteria and have in vivo efficacy in animals.
Type:
Application
Filed:
July 31, 2001
Publication date:
May 9, 2002
Inventors:
Wenying Li, John Leet, Xiaohua Huang, Kin Sing Lam, Alicia Regueiro-Ren
Abstract: This invention provides tissue selective estrogens of formula I having the structure
wherein:
R1 and R2 are independently, hydrogen, alkyl chain of 1-6 carbon atoms, benzyl, acyl of 2-7 carbon atoms, benzoyl,
X is hydrogen, alkyl of 1-6 carbon atoms, CN, halogen, trifluoromethyl, or thioalkyl of 1-6 carbon atoms;
n=1-3;
with the proviso that at least one of R1 or R2 are not hydrogen, alkyl chain of 1-6 carbon atoms, benzyl, acyl of 2-7 carbon atoms, or benzoyl;
or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
September 11, 2000
Date of Patent:
April 30, 2002
Assignee:
American Home Products Corporation
Inventors:
Chris P. Miller, Michael D. Collini, Bach D. Tran, Anita Wai-Yin Chan, Arkadiy Z. Rubezhov
Abstract: Disclosed are novel coumarin based fluorogenic compounds useful in assaying for biological activity. Specifically, these fluorogenic compounds exhibit fluorescence at particular wavelengths when cleaved by target enzymes. Preferred compounds include sugar and peptide derivatives of umbelliferone derivatives bearing a heterocyclic five membered ring at the 3-position. These compounds can be used for rapidly detecting food pathogens and for determining sterilization effectiveness. The compounds may also be used in a form bounded to a polymeric support or to a biomolecule or macromolecule.
Type:
Grant
Filed:
July 7, 2000
Date of Patent:
April 16, 2002
Assignee:
3M Innovative Properties Company
Inventors:
James Gregory Bentsen, Christopher Allen Mickelson, Orlin Bruce Knudson, Kevin Michael Lewandowski
Abstract: Substituted propanolamine derivatives, their pharmaceutically tolerated salts and physiologically functional derivatives thereof are described.
Type:
Application
Filed:
April 13, 2001
Publication date:
April 11, 2002
Applicant:
Hoechst Marion Roussel Deutschland GmbH
Abstract: Disclosed are prodrugs as follows:
(I) a prodrug of the formula
where A is a sulfur or a selenium, and R is a mono- di- or oligo-saccharide;
(II) a prodrug of the formula
where A is sulfur or selenium, R′ is a sugar, or ═O, and the R″ groups are hydrogen, alkyl, alkoxy, carboxy;
(III) a conjugate of an antioxidant vitamin and a thiolamine or selenolamine;
(IV) a prodrug of the formula
where A is sulfur or selenium, and R′ is a sugar, or an alkyl or aryl group, or ═O, and R‡ is an alkoxy, or an amine group;
(V) a prodrug of the formula
R is COOH or H, and R′ is a sugar or ═O.
Type:
Grant
Filed:
July 20, 2000
Date of Patent:
January 22, 2002
Assignee:
University of Utah
Inventors:
Jeannette C. Roberts, Britta H. Wilmore, Pamela B. Cassidy, Pamela K. Dominick, Megan D. Short
Abstract: Apomorphine derivative compounds; pharmaceutically active compositions of apomorphine derivative compounds; and the use of apomorphine derivative compounds in methods for treating sexual dysfunction or for enhancing apomorphine effectiveness for patients treated with apomorphine are disclosed. The apomorphine derivatives may be esters, ethers, amides, mixed anhydrides, hemiacetals, glucuronates, sulfates or phosphonates. A preferred apomorphine derivative is norapomorphine.
Type:
Application
Filed:
March 29, 2001
Publication date:
January 3, 2002
Inventors:
Pramod K. Gupta, Deborah Milkowski, Debra Sutkowski-Markmann
Abstract: The invention provides metabolites of the compound 2-amino-N[2-(3a(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyl-oxymethyl-2-oxo-ethyl]-isobutyramide, the racemic-diastereomeric mixtures and optical isomers thereof, the prodrugs thereof, and the pharmaceutically acceptable salts of the metabolites, racemic-diastereomeric mixtures, optical isomers, and prodrugs; to pharmaceutical compositions thereof; and to methods of using the metabolites and the compositions in the treatment of diseases associated with reduced levels of growth hormone.
Abstract: The present invention relates to processes for preparing protected silylated clarithromycin oxime, preferably 6-O-methyl-2′, 4″-bis(trimethylsilyl)-erythromycin A 9-O-(2-methoxyprop-2-yl)oxime (“S-MOP oxime”), and for converting protected silylated clarithromycin oxime, preferably S-MOP oxime, to clarithromycin. Processes for preparing protected silylated clarithromycin oxime according to the present invention, include reacting a silyl oxime derivative with methylating agent in the presence of at least one solvent and a base, where the solvent comprises methyl tertbutyl ether.
Type:
Application
Filed:
December 15, 2000
Publication date:
November 1, 2001
Inventors:
Ilya Avrutov, Igor Lifshitz, Elizabeth Lewiner
Abstract: The present invention provides an improved method of preparing a 4,7-di-O-alkyl chromogenic ketoside of N-acetylneuraminic acid (Neu5Ac) for use in detecting influenza virus types A and B. The ketosides are substrates that are selectively cleaved by a neuraminidase on influenza virus, but not be neuraminidases found on other viruses or on bacteria. The synthesis is efficient and provides large quantities of the ketoside for commercial development. The synthesis includes a step of alkylating the 4- and 7-hydroxyl groups of a protected alkyl ester alkyl ketoside derivative of Neu5Ac by a process that comprises contacting the derivative with a composition comprising an alkyl halide to form a 4,7-di-O-alkyl protected alkyl ester alkyl ketoside derivative of Neu5Ac. The synthesis alternatively includes protecting the 8- and 9-hydroxyl groups of an alkyl ester alkyl ketoside derivative of Neu5Ac by forming an 8,9-epoxide protected alkyl ester alkyl ketoside derivative of Neu5Ac.
Abstract: The present invention relates to a novel class of glycoside indoles. More specifically, the present invention relates to a novel class of glycoside indoles isolated from Calanthe discolor Lindl. and derivatives thereof.
Abstract: A human cancer cell line bioassay-directed investigation of the Western Pacific marine sponge agelas sp. led to isolation of a trace (7.42×10−6% yield) cancer cell growth inhibitor (lung NCI-H460 GI50 0.77 &mgr;g/ml to ovary OVCAR-3 GI50 2.8 &mgr;g/ml) designated agelagalastatin. Agelagalastatin is the first example of a natural product containing a digalactofuranosyl unit.
Abstract: An aminoalcohol derivative which is a ceramide analogue, and a medicament, especially an agent for treating neuronal diseases and an agent for protecting brain, comprising the same.
Abstract: Substituted propanolamine derivatives, their pharmaceutically tolerated salts and physiologically functional derivatives thereof are described.
Also described are compounds of formula I
in which the radicals have the abovementioned meanings, and their physiologically tolerated salts, physiologically functional derivates and processes for their preparation. The compounds are suitable as, for example, hypolipidemics.
Abstract: The present invention includes polymerizable monomers comprising an acid-functionalized glycoside moiety. The monomer can have a polymerizable functional group, such as an olefinic bond, to which the acid-functionalized glycoside moiety is attached by a spacer group, for example, an alkylene group, or an alkylene group wherein one or more carbon atoms are substituted by heteroatoms, such as oxygen, nitrogen or sulfur atoms. The present invention also includes polymers comprising pendant acid-functionalized glycoside moieties. The present invention also provides a method for treating a microbial infection in a mammal by administering to the mammal a therapeutically effective amount of a polymer comprising one or more acid-functionalized glycoside moieties.
Type:
Grant
Filed:
June 1, 2000
Date of Patent:
May 22, 2001
Assignee:
GelTex Pharmaceuticals, Inc.
Inventors:
W. Harry Mandeville, III, Venkata R. Garigapati
Abstract: A new class of N-linked Lewis and LacNAc analogs of are synthesized and shown to be effective inhibitors of human fucosyltransferases. In a high yielding reaction sequence the glucosamine derivative 1 was transformed to the 3-azido-2,3-dideoxy sugar 2e under excellent stereocontrol. The LacNAc analog 4d was synthesized as a single isomer in three steps starting from 2e. In a one pot procedure iminocyclitol 5 was transformed into aldehyde 6 and successfully used for reductive amination with 4c and 2f yielding trisaccharide 8a, and disaccharide 7a.
Abstract: The present invention provides fluorescent nucleosides carrying polycyclic aromatic hydrocarbons such as anthracene, phenanthrene, pyrene stilbene, tetracene or pentacene. The subject nucleosides may be synthesized using a C-glycosidic bond formation method employing organocadmium or organozinc derivatives of the aromatic compounds and coupling with a 1-&agr;-chlororibose or deoxyribose synthon. The &agr;-anomers of the coupling reaction may be epimerized to the &bgr;-anomers by acid-catalyzed equilibration. The fluorescent nucleosides act as DNA or RNA base analogs and can be incorporated into nucleic acids. Resultant fluorescently tagged nucleic acids are useful as probes for target nucleic acids in tissues, solutions or immobilized on membranes.
Abstract: Synthesis of an amino-disaccharide, amino-oligosaccharide or a derivative thereof, characterized in that a monosaccharide, a disaccharide, an oligosaccharide, a glycoside or a derivative thereof, in the presence of a glycosidase as catalyst, is reacted with an amino-deoxy-saccharide or a glycoside or derivative thereof, and that the amino-saccharide is optionally isolated from the product mixture directly or after chemical/enzymatic modification.
Abstract: A new crystalline form of morphine-6-glucuronide, referred to as Form A, characterized by its infrared spectrum pattern and/or by its x-ray powder diffraction image, the use thereof and a process for the preparation thereof.
Type:
Grant
Filed:
November 4, 1999
Date of Patent:
January 9, 2001
Assignee:
CeNeS Ltd.
Inventors:
Herwig Schneider, Rudolph Franzmair, Andreas Koch, Franz Rovensky